GCC Sickle Cell Disease Disease Landscape

Sickle cell disease (SCD) burden in the GCC is disproportionate on a global scale: Saudi Arabia alone carries an estimated 140,000–200,000 SCD patients, reflecting carrier rates of 6–7% in the Eastern Province and 3–4% nationally, with significant HbSS and HbSS/HbC compound heterozygosity; Bahrain reports 2–3% adult prevalence and parts of Oman 3–5%. This makes the GCC one of the highest per-capita SCD burden regions outside sub-Saharan Africa, a legacy of historic trade-route population mixing along the Persian Gulf and Arabian Sea. Mandatory premarital carrier screening, in place nationally in Saudi Arabia, has reduced new HbSS births by an estimated 15–20% annually since implementation — the single most effective GCC-specific intervention to date, even as the existing patient population remains very large.

Inadequately treated GCC SCD patients experience 8–12 vaso-occlusive crisis (VOC) episodes per year and 4–6 hospital admissions annually for severe disease, alongside substantial chronic organ damage: pulmonary hypertension in an estimated 20% of echo-screened patients, avascular necrosis of the hip or shoulder in 30–40%, and stroke history in roughly 10%, lower than comparable US cohorts and attributed to transfusion exchange programmes at major centres. Annual cost per GCC SCD patient runs SAR 180,000–300,000 including hospitalisation, transfusion, and chelation. The patient pathway typically runs from newborn screening (in place across most GCC states) through paediatric haematology to an adult haematology transition at age 18–21 — a transition that is poorly managed outside KFSH&RC, KAMC, and AUH, which maintain structured adult SCD programmes; most other GCC hospitals manage adult SCD within general internal medicine without dedicated haematology oversight.

This assessment is built from the NPHC Saudi SCD programme evaluation, the KFSH&RC SCD outcomes registry, and peer-reviewed regional epidemiological literature, triangulated to separate prevalent population scale from the premarital-screening-driven incidence trend.

Formulary and access status is confirmed against NPHC and MOH listings and SFDA registration records rather than US/EU payer language, reflecting the fact that NPHC governs KSA access separately from MOH programmes in the UAE, Qatar, and Bahrain.